184 related articles for article (PubMed ID: 19709980)
1. Depression in hospitalized patients with malignant melanoma treated with interferon-alpha-2b: primary to induced disorders.
Navinés R; Gómez-Gil E; Puig S; Baeza I; De Pablo J; Martín-Santos R
Eur J Dermatol; 2009; 19(6):611-5. PubMed ID: 19709980
[TBL] [Abstract][Full Text] [Related]
2. Depressive mood changes and psychiatric symptoms during 12-month low-dose interferon-alpha treatment in patients with malignant melanoma: results from the multicenter DeCOG trial.
Heinze S; Egberts F; Rötzer S; Volkenandt M; Tilgen W; Linse R; Boettjer J; Vogt T; Spieth K; Eigentler T; Brockmeyer NH; Hinzpeter A; Hauschild A; Schaefer M
J Immunother; 2010 Jan; 33(1):106-14. PubMed ID: 19952950
[TBL] [Abstract][Full Text] [Related]
3. Dose-dependent development of depressive symptoms during adjuvant interferon-{alpha} treatment of patients with malignant melanoma.
Friebe A; Horn M; Schmidt F; Janssen G; Schmid-Wendtner MH; Volkenandt M; Hauschild A; Goldsmith CH; Schaefer M
Psychosomatics; 2010; 51(6):466-73. PubMed ID: 21051677
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment levels of sTNF-R1 and sIL-6R are associated with a higher vulnerability for IFN-alpha-induced depressive symptoms in patients with malignant melanoma.
Friebe A; Schwarz MJ; Schmid-Wendtner M; Volkenandt M; Schmidt F; Horn M; Janssen G; Schaefer M
J Immunother; 2007 Apr; 30(3):333-7. PubMed ID: 17414324
[TBL] [Abstract][Full Text] [Related]
5. Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy.
Capuron L; Ravaud A; Miller AH; Dantzer R
Brain Behav Immun; 2004 May; 18(3):205-13. PubMed ID: 15050647
[TBL] [Abstract][Full Text] [Related]
6. Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy.
Capuron L; Ravaud A; Dantzer R
J Clin Oncol; 2000 May; 18(10):2143-51. PubMed ID: 10811680
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant therapy of melanoma with interferon-alpha-2b is associated with mania and bipolar syndromes.
Greenberg DB; Jonasch E; Gadd MA; Ryan BF; Everett JR; Sober AJ; Mihm MA; Tanabe KK; Ott M; Haluska FG
Cancer; 2000 Jul; 89(2):356-62. PubMed ID: 10918166
[TBL] [Abstract][Full Text] [Related]
8. Psychopharmacological treatment of depression, anxiety, irritability and insomnia in patients receiving interferon-alpha: a prospective case series and a discussion of biological mechanisms.
Maddock C; Baita A; Orrù MG; Sitzia R; Costa A; Muntoni E; Farci MG; Carpiniello B; Pariante CM
J Psychopharmacol; 2004 Mar; 18(1):41-6. PubMed ID: 15107183
[TBL] [Abstract][Full Text] [Related]
9. Methylphenidate for alpha-interferon induced depression.
Camacho A; Ng B
J Psychopharmacol; 2006 Sep; 20(5):687-9. PubMed ID: 16533869
[TBL] [Abstract][Full Text] [Related]
10. Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanoma.
Hauschild A; Weichenthal M; Rass K; Linse R; Ulrich J; Stadler R; Volkenandt M; Grabbe S; Proske U; Schadendorf D; Brockmeyer N; Vogt T; Rompel R; Kaufmann R; Kaatz M; Näher H; Mohr P; Eigentler T; Livingstone E; Garbe C
J Clin Oncol; 2009 Jul; 27(21):3496-502. PubMed ID: 19433681
[TBL] [Abstract][Full Text] [Related]
11. Correlation between sICAM-1 and depressive symptoms during adjuvant treatment of melanoma with interferon-alpha.
Schaefer M; Horn M; Schmidt F; Schmid-Wendtner MH; Volkenandt M; Ackenheil M; Mueller N; Schwarz MJ
Brain Behav Immun; 2004 Nov; 18(6):555-62. PubMed ID: 15331126
[TBL] [Abstract][Full Text] [Related]
12. Severe action tremor related to interferon-alpha 2b therapy for malignant melanoma.
Nishihori T; Abdo-Matkiwsky M; Fleishman SB; Blum RH
Am J Clin Oncol; 2005 Oct; 28(5):526. PubMed ID: 16199995
[TBL] [Abstract][Full Text] [Related]
13. Major depression and risk of depressive symptomatology associated with short-term and low-dose interferon-alpha treatment.
Beratis S; Katrivanou A; Georgiou S; Monastirli A; Pasmatzi E; Gourzis P; Tsambaos D
J Psychosom Res; 2005 Jan; 58(1):15-8. PubMed ID: 15771865
[TBL] [Abstract][Full Text] [Related]
14. Neuropsychiatric complications associated with interferon-alpha-2b treatment of malignant melanoma.
Okereke OI
Psychosomatics; 2002; 43(3):237-40. PubMed ID: 12075040
[No Abstract] [Full Text] [Related]
15. Interferon-alpha in oncology patients: fewer psychiatric side effects than anticipated.
Bannink M; Kruit WH; Van Gool AR; Sleijfer S; van der Holt B; Eggermont AM; Stoter G; Hengeveld MW
Psychosomatics; 2008; 49(1):56-63. PubMed ID: 18212177
[TBL] [Abstract][Full Text] [Related]
16. [Alpha-interferon and mental disorders].
Debien C; De Chouly De Lenclave MB; Foutrein P; Bailly D
Encephale; 2001; 27(4):308-17. PubMed ID: 11686052
[TBL] [Abstract][Full Text] [Related]
17. Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma.
Alatrash G; Hutson TE; Molto L; Richmond A; Nemec C; Mekhail T; Elson P; Tannenbaum C; Olencki T; Finke J; Bukowski RM
J Clin Oncol; 2004 Jul; 22(14):2891-900. PubMed ID: 15254058
[TBL] [Abstract][Full Text] [Related]
18. Interstitial pneumonitis in a patient with melanoma treated with the high dose interferon alpha 2b regimen.
Siegelmann-Danieli N; Bardo M; Law A; Fisk D; Bernath A
Isr Med Assoc J; 2004 Oct; 6(10):636-7. PubMed ID: 15473596
[No Abstract] [Full Text] [Related]
19. Social support decreases depressogenic effect of low-dose interferon alpha treatment in melanoma patients.
Kovács P; Pánczél G; Balatoni T; Liszkay G; Gonda X; Bagdy G; Juhasz G
J Psychosom Res; 2015 Jun; 78(6):579-84. PubMed ID: 25801845
[TBL] [Abstract][Full Text] [Related]
20. [Depressive symptoms during treatment with interferon alpha for HCV infection--preliminary report].
Małyszczak K; Inglot M; Pawłowski T; Czarnecki M; Rymer W; Andrzej K
Psychiatr Pol; 2006; 40(4):799-808. PubMed ID: 17068951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
